Committee for Medicinal Products for Human Use
![ptc therapeutics layoffs, translarna loses eu approval, dmd drug ptc layoffs, translarna dmd drug eu loss, ptc cuts jobs dmd drug setback, translarna withdrawal europe, ptc dmd drug revenue loss,](https://pharmtales.com/wp-content/uploads/2023/09/PTC-cuts-jobs-as-Europe-withdraws-approval-for-its-DMD-drug.jpg)
PTC cuts jobs as Europe withdraws approval for its DMD drug
PTC Therapeutics has announced an expansion of its previously planned workforce reductions as European regulatory concerns cast a shadow over ...
![Duchenne muscular dystrophy, PTC Therapeutics, European Medicines Agency, Translarna, Committee for Medicinal Products for Human Use](https://pharmtales.com/wp-content/uploads/2023/09/PTC-Therapeutics-Translarna-at-risk-of-losing-EU-approval-after-failing-to-impress-FDA-for-DMD.jpg)
PTC Therapeutics’ Translarna at risk of losing EU approval after failing to impress FDA for DMD
PTC Therapeutics is facing a significant setback as it seeks to maintain approval for its Duchenne muscular dystrophy (DMD) therapy, ...
![Omicron variant, Omicron vaccine, Pfizer, BioNTech, CHMP positive opinion, Committee for Medicinal Products for Human Use](https://pharmtales.com/wp-content/uploads/2023/09/Pfizer-and-BioNTech-Get-Green-Light-for-Omicron-Vaccine-in-Europe-by-CHMP.jpg)
Pfizer and BioNTech Get Green Light for Omicron Vaccine in Europe by CHMP
Pfizer and BioNTech have unveiled their latest breakthrough in the post COVID era. Brace yourselves for the Omicron XBB.1.5-adapted monovalent ...
![Pfizer, Committee for Medicinal Products for Human Use, European Commission, Respiratory syncytial virus, Abrysvo, EC approval, Pfizer Abrysvo,](https://pharmtales.com/wp-content/uploads/2023/08/Europe-Approves-Pfizers-Abrysvo-a-Novel-Vaccine-for-RSV.jpg)
EC Approves Pfizer’s Abrysvo, Only RSV vaccine in EU for adults and infants
Pfizer has just received approval from the European Commission (EC) for its groundbreaking vaccine, Abrysvo. This vaccine, targeting the respiratory ...
![AbbVie Receives Favorable CHMP Opinion for Atogepant as Preventive Treatment for Migraine in Adults](https://pharmtales.com/wp-content/uploads/2023/06/AbbVie-Receives-Favorable-CHMP-Opinion-for-Atogepant-as-Preventive-Treatment-for-Migraine-in-Adults.jpg)
AbbVie Receives Favorable CHMP Opinion for Atogepant as Preventive Treatment for Migraine in Adults
Source – AbbVie AbbVie announced on June 23, 2023, that the Committee for Medicinal Products for Human Use (CHMP) of ...